Monthly Archives: October 2011

Commercialization and Job Creation in the Biotechnology Sector

Doug Crawford

It’s tough presenting programs on technology transfer because so much has already been said that it’s hard to find something new. However, that was not a problem this week in San Francisco at the BIO Technology Transfer Symposium. The Symposium began with an overview of the efforts by the Obama Administration to spur innovation including funding macro and micro grants to encourage the development of regional technology clusters, and proof of concept centers to help Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Beyond the ABCs of ADCs

Antibody

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Resistance is Futile – SuperDrugs for SuperBugs

800px-Acinetobacter_baumannii

“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, Rib-X Pharmaceuticals, Inc. With new superbugs on the rise and new superdrugs continuing to decline, the antibacterial drug discovery market is anyone’s for the taking. Attendees of the 10th Annual BIO Investor Forum participating in the Infectious Disease Therapeutic Workshop heard from an engaging panel that seemed to agree the economics of this category are driven by two things: society expects Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice

oncology

Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Multiple Assets Diversify the Deal

Partnering Meeting

With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery stage partnering deals are becoming increasingly popular.  Striking a discovery stage deal can be extremely beneficial for both parties in today’s environment – pharma gets to fill its ever elusive R&D pipeline as patent expirations loom, and the small biotech struggling to raise money to stay alive gets the capital infusion necessary to stay in play. Panelists in the “Broad Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,